Zealand PharmaRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Zealand Pharma (ZEAL.CO) reported revenue of $692.00M in Q2 2026.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
Zealand PharmaDanish biotech focused on peptide therapeutics. Petrelintide (amylin analog monotherapy, Phase 2, Roche partnership); dapiglutide; survodutide (Phase 3 dual GLP-1/glucagon partnered with Boehringer Ingelheim).
Zealand Pharma (ZEAL.CO) is a Biotechnology company. Danish biotech focused on peptide therapeutics. Petrelintide (amylin analog monotherapy, Phase 2, Roche partnership); dapiglutide; survodutide (Phase 3 dual GLP-1/glucagon partnered with Boehringer Ingelheim). It was founded in 1998, is headquartered in Søborg, Denmark and employs about 220 people.
Track Zealand Pharma's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 17, 2026.
Sterling groups Zealand Pharma in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Zealand Pharma, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.